These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8139841)

  • 41. The actual incidence of bladder perforation following transurethral bladder surgery.
    Balbay MD; Cimentepe E; Unsal A; Bayrak O; Koç A; Akbulut Z
    J Urol; 2005 Dec; 174(6):2260-2, discussion 2262-3. PubMed ID: 16280794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Destruction of bladder neoplasms by means of transurethral neodym-YAG-laser coagulation].
    Staehler G; Schmiedt E; Hofstetter A
    Helv Chir Acta; 1978 Jul; 45(3):307-11. PubMed ID: 568126
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma.
    Li LY; Yang M; Zhang HB; Su XK; Xu WF; Chen Y; Shen ZJ; Gao X
    BJU Int; 2008 Aug; 102(5):566-71. PubMed ID: 18410436
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Endoscopic Nd-YAG laser therapy and tracheobronchial surgery].
    Nishimura Y; Ikeda T; Sakai T; Horinouchi H
    Kyobu Geka; 1992 Jan; 45(1):40-4. PubMed ID: 1735939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
    Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
    BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
    J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
    Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
    Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of xanthelasma palpebrarum by 1064-nm Q-switched Nd:YAG laser: a study of 11 cases.
    Fusade T
    Br J Dermatol; 2008 Jan; 158(1):84-7. PubMed ID: 17916214
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Prognostic factors of superficial bladder cancer recurring after initial transurethral resection].
    Nakata S; Nakano K; Takahashi H; Shimizu K
    Hinyokika Kiyo; 2005 Apr; 51(4):229-33. PubMed ID: 15912780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of 120W high performance system greenlight laser vaporization for non-muscle-invasive bladder cancer.
    Tao W; Yang D; Shan Y; Xue B; Sun C; Zang Y; Zhang Y
    J Xray Sci Technol; 2013; 21(2):309-16. PubMed ID: 23694918
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of digestive tract tumors using the Nd-YAG laser].
    Mlkvý P; Králik G; Plesko B
    Vnitr Lek; 1989 Jul; 35(7):679-84. PubMed ID: 2800374
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The complications of transurethral resection of the bladder for tumor].
    Chepurov AK; Nemenova AA
    Urol Nefrol (Mosk); 1996; (2):21-3. PubMed ID: 8677546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Application possibilities for Neodym-YAG lasers in urology].
    Staehler G
    Z Urol Nephrol; 1982 Oct; 75(10):711-21. PubMed ID: 7158090
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Role of fluorescent control in raising radicality of surgical treatment for superficial bladder cancer].
    Matveev BP; Kudashev BV; Bukharkin BV; Romanov VA; Rubanov IuV
    Urologiia; 2000; (3):22-4. PubMed ID: 11186703
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The value of a second transurethral resection in evaluating patients with bladder tumors.
    Herr HW
    J Urol; 1999 Jul; 162(1):74-6. PubMed ID: 10379743
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Use of Nd:YAG laser for treatment of basal-cell carcinomas and some premalignant conditions].
    Rubisz-Brzezińska J; Bendkowski W
    Przegl Dermatol; 1990; 77(6):385-8. PubMed ID: 2287739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nd: YAG laser treatment of vesical leiomyosarcoma.
    Gaboardi F; Bordinazzo R; Bersiga A; Galli L
    Arch Esp Urol; 1989 Apr; 42(3):288-9. PubMed ID: 2690754
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Experience with the use of neodymium YAG laser in urology (author's transl)].
    Staehler G
    MMW Munch Med Wochenschr; 1980 Nov; 122(45):1603-6. PubMed ID: 6779129
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical experience with the ND-YAG laser in intravesical and intra-urethral pathology].
    Braeckman J; Vanwaeyenbergh J; Corujeira-Figueira F; Keuppens F
    Acta Urol Belg; 1989; 57(3):703-6. PubMed ID: 2816586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.